Paxil CR Labeling Adds New Data On Birth Defects; GSK Plans Further Studies
Executive Summary
GlaxoSmithKline is conducting additional epidemiologic studies to better understand preliminary data suggesting a potential link between paroxetine use and birth defects, the company said in a "Dear Doctor" letter on revised labeling for Paxil CR and Paxil